Background: Capsular contracture (CC) is a major complication of breast surgery with smooth and textured implants. Polyurethane (PU) foam-coated breast implants were developed to decrease the incidence of CC. Objectives: The authors determined the incidence of CC following 2-stage breast reconstruction using PU foam-covered implants, with and without radiation therapy. Methods: The records of 92 patients who received 115 PU implants were retrospectively reviewed. The rates of CC over time were compared for irradiated and nonirradiated groups with a Kaplan-Meier analysis and log-rank test. CC rates also were analyzed with respect to age. Results: The median follow-up time for patients was 103.3 months. Nine patients experienced unilateral Baker grade III or IV fibrous CC, including 6 patients from the irradiated group and 3 patients from the nonirradiated group. The overall cumulative incidence of CC at 9 years was 8.1%. In the irradiated and nonirradiated groups, the 9-year cumulative incidence was 10.7% and 5.5%, respectively. CC occurred within 3 years in the irradiated group and within 7 years in the nonirradiated group. The incidence of CC appeared to be higher among younger patients. Conclusions: Radiation therapy increases the risk of high-grade CC with textured or smooth implants. PU implants are associated with a much lower cumulative incidence of CC following 2-stage breast reconstruction, even when radiotherapy is performed.
Since the introduction of breast implants in plastic surgery nearly 50 years ago, capsular contracture (CC) has been the leading cause of morbidity and reoperation, with reported incidences as high as 80%. [1] [2] [3] Results of many studies have shown that the incidence of CC is higher for breast reconstruction than for primary cosmetic breast augmentation. [4] [5] [6] [7] [8] [9] [10] According to the US Food and Drug Administration, women who received reconstruction with silicone gel implants had a nearly 15% risk of CC (Baker grade III or IV), a 25% risk of implant removal or replacement, and an overall reoperation rate of 40% at the end of 4 years. 11 Radiation therapy (RT) also appears to increase the risk of CC. In several studies of 2-stage breast reconstruction, the incidence of CC was consistently higher for patients who also underwent RT compared with those who did not receive RT. [12] [13] [14] [15] Authors of a long-term prospective analysis of a large cohort of women found that CC of grade III or IV occurred in 46.6% of irradiated implants but in only 6.4% of nonirradiated implants. 16 To decrease the high incidence of CC associated with silicone breast implants, polyurethane (PU) foam-coated implants were introduced (by Ashley 17 in 1970). Many investigators have found that the incidence of CC with PU-coated implants is approximately 2%. 3, 5, [18] [19] [20] [21] [22] [23] [24] [25] However, data are scarce regarding the incidence of CC among women who receive PU foam-coated implants during 2-stage breast reconstruction, particularly when the procedure is combined with RT. We sought to determine the long-term incidence of CC following 2-stage breast reconstruction with PU implants in the presence and absence of RT. The secondary outcome was to examine the association between patient age and occurrence of CC.
METHODS

Study Design
For this retrospective cohort study, we reviewed the medical records of patients (all female) who underwent immediate 2-stage breast reconstruction with PU-coated shaped implants with or without RT from June 2002 through February 2015 (12 years, 8 months) at Sandro Pertini Hospital (Rome, Italy). This study was approved by the ethics review board of the hospital. Exclusion criteria were 1-stage breast reconstruction, delayed reconstruction, secondary breast surgery, and any reconstruction involving round implants, smooth or textured implants, saline implants, acellular dermal matrix, or autologous tissue.
An Excel database was prepared with information for 92 patients (115 breast implants). The following variables were included: diagnosis; patient age; date of mastectomy and placement of tissue expander; date of implantation with the PU device; need for RT; implant type, size, and projection; length of follow-up and dates of follow-up visits; and presence and grade of CC. The original patient database, which included all early and late complications, was refined for this study to only indicate CC occurrence during follow-up.
Surgical Techniques
Consultations and surgical procedures were performed by the senior surgeon (S.P.) or members of his team at Sandro Pertini Hospital. All patients underwent mastectomy with immediate 2-stage breast reconstruction. Round or lowheight tissue expanders were positioned subpectorally. One or 2 drains were placed, depending on whether the expander was partially or fully covered by the muscle, respectively. Patients who underwent RT received a mean dose of 50 Gy, over the tissue expander only, between 1 and 6 months (mean, 3 months) after the first surgical session and a mean of 3 months prior to placement of the definitive PU-coated implant. Implant choice was based on the surgeon's recommendation. None of the definitive implants was irradiated. All shaped gel implants were covered with MPS, a micro-PU foam (Microthane, Polytech Health & Aesthetics, Dieburg, Germany).
Determination of CC Incidence
Patients were monitored at follow-up visits attended by at least 4 of the 5 senior team members at 1, 3, and 6 months postoperatively. CC was graded by the Baker scale; cases of grades III and IV CC were evaluated further in this study. Grade III CC corresponds to a hard breast and noticeable implant. Grade IV CC denotes a hard and rigid implant with stretched and tender skin, pain, and distortion of the breast. Capsulectomy, excluding the chest wall, was performed when the overlying tissues were sufficiently thick. For patients with inadequate tissue coverage, partial capsulectomy was performed to promote tissue adhesion to the PU surface of the implant and avoid further depletion of the overlying tissues.
Statistical Analysis
An independent epidemiologist (G.F.) performed data analysis. Because the primary objective of this study was to determine the role of micro-PU foam in the prevention of high-grade CC (Baker III or IV) after primary breast reconstruction, we evaluated individual breast implants rather than individual patients. Breast implants were categorized as irradiated or nonirradiated group. "Time to CC" was defined as the time from the first surgical session to the diagnosis of CC. Patients without a diagnosis of CC were censored at last follow-up or death. Rates of CC, determined for 12-month periods, were estimated with the KaplanMeier method, with cumulative incidences and 95% confidence intervals (CI). Cumulative incidence curves, stratified by irradiation status and age, were compared with the log-rank test for equality of survivor functions. A multivariate Cox proportional hazards model was applied to study the association between CC and age while controlling for irradiation status. Statistical significance was defined as P < .05. All analyses were performed with Stata 13 statistical software (StataCorp LP, College Station, TX).
RESULTS
Sixty-nine of the 92 patients underwent unilateral mastectomy, and 23 underwent bilateral mastectomy. Of the 115 breasts, 64 underwent skin-sparing mastectomy, 26 received nipple-sparing mastectomy, 17 required radical mastectomy, and 8 underwent skin-reducing mastectomy. Fifty-six breasts (49 patients) were irradiated, and 59 breasts (43 patients) were nonirradiated (Tables 1 and 2 ). The need for RT could not be predicted in any case.
The patients' mean age was 53 years (standard deviation [SD], 10.2 years; range, 27-76 years), and the median follow-up was 103.3 months (range, 6.2-152.4 months) ( Table 1) . When the study population was analyzed in terms of individual breast implants, the mean age of implants for the nonirradiated group was 54.6 years (SD, 8.6 years; range, 39-75 years), and the mean age for the irradiated group was 50.8 years (SD, 10.5 years; range, 27-76 years) ( Table 2 ). The median follow-up time was 103.9 months (range, 33.8-152.4 months) for the nonirradiated group and 106.6 months (range, 6.2-151.6 months) for the irradiated group (Table 2) .
Fibrous CC (Baker grade III or IV) developed in 9 breast implants (9 patients). Each patient who experienced fibrous CC had undergone unilateral mastectomy. Four cases of CC occurred within the first year following implant placement, additional 3 cases occurred within 3 years, and the remaining 2 cases occurred within 7 years. The cumulative incidence of CC at 9 years was 8.1% (95% CI, 4.3-15.0), as shown in Figure 1 . KaplanMeier survival curves depicted the likelihood of CC over time, with and without RT (Figure 2) . Of the 9 breasts that developed CC, 6 had been irradiated. Four of these breasts developed CC within 1 year, and 2 developed CC within 3 years. The cumulative incidence of CC at 9 years in this group was 10.7% (95% CI, 5.0-22.3). For the 3 nonirradiated breasts that developed CC, this complication was diagnosed 3 to 7 years after implantation. The cumulative incidence of CC at 9 years in this group was Kaplan-Meier cumulative incidence depicting the rates of capsular contracture (CC) after 2-stage breast reconstruction according to irradiation status. Nonirradiated group, blue curve (n = 59 breast implants). Irradiated group, red curve (n = 56 breast implants). Radiation therapy (RT) was delivered over the tissue expander. Reliable data were available for a median of 9 years of follow-up.
5.5% (95% CI, 1.8-16.1).
No statistically significant difference was observed for the cumulative incidence curves for irradiated and nonirradiated groups (log-rank test, P = .23).
To evaluate the role of age in CC occurrence, the PU-coated implants were stratified in two groups using the median age of patients (53 years) as the cut-off value. Fifty-nine breast implants corresponded to patients who were younger (27-52 years old), and 56 breast implants corresponded to patients who were older (53-76 years old). Seven of the 9 breasts with CC, which developed within 7 years, were in the younger group. The remaining 2 breasts with CC, which developed within 2 years, were in the older group (Figure 3) . The cumulative incidence of CC at 9 years was 12.2% (95% CI, 6.0-23.9) in the younger group and 3.6% (95% CI, 0.9-13.5) in the older group. The difference between the 2 curves, as determined by the logrank test, was not statistically significant (P = .10).
Additional epidemiologic analysis was performed to exclude confounding by RT in the association between age and CC. Even after adjustment of the Cox proportional hazards model for RT, the occurrence of CC appeared to be lower among older patients than younger ones (hazard ratio, 0.31; P = .15).
DISCUSSION
Breast augmentation with PU foam-coated implants is associated with a very low risk of CC. 3, 5, 19, 21, 22, [24] [25] [26] In the current study, the 9-year incidence of CC after breast reconstruction with PU implants in nonirradiated breasts was 5.5% (median follow-up, 9 years), which coincides with the results of other investigators. 3, [27] [28] [29] This rate of CC is among the lowest reported after 2-stage breast reconstruction with textured implants. 16 The results of other studies, in which textured breast implants were monitored for a similar duration, have indicated that a low rate of CC is not guaranteed with these implants. For example, the 10-year incidence of CC associated with Biocell textured implants (Inamed Aesthetics, Santa Barbara, CA) was 14.5% for patients who underwent primary reconstruction, presumably without RT. 30 The CC rate at 9 years for Siltex shaped implants (Mentor, Santa Barbara, CA) was 12.7% for a series of patients who received primary breast reconstruction without specified RT. 31 The CC incidence at 9 years for textured Sientra implants (Sientra, Inc, Santa Barbara, CA) under the same conditions was 14.4%. 32, 33 We found that the incidence of CC following 2-stage breast reconstruction with RT (10.7%; median follow-up, 9 years) reminded the encouraging CC rate for the group that did not receive RT (5.5%; median follow-up, 9 years) ( Figure 2 ). Investigators worldwide have suggested that RT exponentially increases the risk of CC. 14,34-36 Rancati et al 23 recently described a very low incidence of CC after 1-step breast reconstruction with PU-coated implants; however, all 4 cases of Baker grade IV CC observed in that study corresponded to patients who underwent RT. Cordeiro et al 16 examined a large cohort of patients who underwent 2-stage breast reconstruction and found that the most common cause (33%) for implant replacement in the subgroup of patients with RT and textured implants was grade III or IV CC. This complication occurred in 46.6% of irradiated breasts (grade III, 39.7%; grade IV, 6.9%). 16 In this retrospective analysis, we observed early onset of CC among patients who underwent 2-stage immediate breast reconstruction with adjuvant RT. Specifically, CC occurred within 3 years after breast implantation. In contrast, other investigators have shown that the incidence of CC after breast augmentation or reconstruction with textured or PU-coated implants increases as a function of time for 10 years or more postoperatively. 3, 5, 24, 30, 37 Szycher and Siciliano 38 have noted that the protective effect of PU foam against CC is enduring, and many authors have confirmed the long-term efficacy and safety of PU foam-coated breast implants. 6, 22, 24, 25 PU foam in the capsule degrades very slowly under the influence of inflammatory cell esterases. 39, 40 Castel et al 24 noted macroscopic evidence of PU on the surface of implants that were explanted up to 5 years postoperatively. However, these authors performed histologic analyses and found that PU persisted in the capsule for 30 years of monitoring. 24 This observation of persistent microscopic PU and our finding of early onset of CC after 2-stage breast reconstruction with RT strengthen the hypothesis that PU-coated implants are more effective than noncoated implants in decreasing the incidence of CC.
We determined the cumulative incidence of CC in a cohort of women who underwent 2-stage breast reconstruction. This study may have benefitted from a comparison group of women who received textured implants with or without RT. However, a retrospective comparison of 2 cohorts would have been highly susceptible to bias. We maintain that a descriptive long-term analysis of a cohort and its comparison with similar international cohorts was the optimal design for this study. Moreover, we previously performed a direct comparison between PU implants and textured implants. 20 A randomized controlled trial in which the CC risk associated with PU-coated implants is observed prospectively and compared directly with that of textured implants would provide more definitive results.
Grade II CC was not included in this study design because the international literature generally does not address this grade, even when the rate of CC is the primary objective of the study. 3, 5, 10, 11, 16, 20, [30] [31] [32] [33] In addition, grade II CC usually is not painful and does not necessitate intervention. We attempted to account for additional risk factors for CC among patients who underwent 2-stage breast reconstruction (eg, body mass index; age). Patient age tended to influence long-term CC, with the younger group (aged 27-52 years) and the older group (aged 53-76 years) exhibiting 9-year CC incidences of 12.2% and 3.6%, respectively. This difference was not statistically significant, which may be attributed to the small sample size. However, statistical analyses of our data excluded RT as a confounding factor in this potential association. An effect of patient age has been observed in clinical practice for other types of fibrosis. For example, hypertrophic scars generally are more common in younger patients, presumably because younger patients are subject to more physical and hormonal changes. 14, [41] [42] [43] Further investigation of this finding is warranted.
CONCLUSIONS
The safety of PU foam-coated implants has been demonstrated in clinical practice for more than 4 decades. Compared with textured implants, PU implants are associated with a lower rate of CC, which is the most common complication of breast reconstruction and a frequent reason for reoperation. This attribute of PU implants does not appear to diminish over time and is particularly attractive for patients who undergo RT. The results of this study confirm the low long-term incidence of CC with PU implants and support that these implants are an effective alternative to textured devices, which have failed to attain the benefits of the foam. We advocate recommending PU foam-coated implants as a first choice for patients who undergo 2-stage breast reconstruction with adjuvant RT.
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